(HealthDay News) — The overall prevalence of venous thromboembolism (VTE) in patients with COVID-19 is estimated to be 14.1%, with a higher prevalence for patients in the intensive care unit (ICU), according to a review published online in Research and Practice in Thrombosis and Haemostasis.

Stephan Nopp, MD, from the Medical University of Vienna, and colleagues conducted a systematic literature search to estimate the prevalence of VTE in patients with COVID-19. Data were identified from 86 studies with 33,970 patients; 66 studies with 28,173 patients were included in a quantitative analysis.

The researchers found that the overall prevalence estimate for VTE was 14.1%; the prevalence estimate was 40.3% with ultrasound screening and 9.5% without screening. High heterogeneity was seen in a subgroup analysis, with a VTE prevalence of 7.9 and 22.7% in non-ICU and ICU patients, respectively. The prevalence of pulmonary embolism was 3.5 and 13.7% in non-ICU and ICU patients, respectively. Higher D-dimer levels were seen in patients developing VTE versus non-VTE patients (weighted mean difference, 3.26 µg/mL).

“There is a clinical need for further research to better understand the risk and prevent VTE in patients with COVID-19,” the authors write. “These findings support the broad use of thromboprophylaxis, specifically in ICU patients.”

Continue Reading

Several authors disclosed financial ties to the pharmaceutical industry.


Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis. Res Prac Thrombosis Haemostasis.